Visgo Therapeutics

Visgo Therapeutics is a clinical-stage biotechnology company based in Taiwan that focuses on developing advanced treatments for orthopedic conditions. The company utilizes its proprietary hydrogel technology platform to develop sustained-release intra-articular injections for the treatment of osteoarthritis and other musculoskeletal disorders. Its lead product candidate, VT-101, is currently in clinical development for knee osteoarthritis, aiming to provide prolonged pain relief and improved joint function. By combining innovative drug delivery systems with established therapeutic agents, Visgo seeks to reduce the frequency of injections and enhance patient outcomes in the orthopedic space.